Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HB-002.1T by Huabo Biopharm (Shanghai) for Extrahepatic Bile Duct Cancer: Likelihood of Approval
HB-002.1T is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Extrahepatic Bile Duct Cancer. According...